DAWN · CIK 0001845337 · operating
Day One Biopharmaceuticals is a commercial-stage biotechnology company developing oral kinase inhibitors for pediatric and adult cancers. The company's lead candidate, tovorafenib, is a brain-penetrant type II pan-RAF kinase inhibitor currently in Phase II trials for pediatric patients with relapsed or refractory low-grade glioma. The company is also advancing tovorafenib in partnership with Ipsen through a Phase III trial as a frontline treatment for RAF-altered pediatric low-grade glioma.
The company's pipeline includes DAY301, a RAF inhibitor in Phase I development for both adult and pediatric cancers, and a VRK1 inhibitor in preclinical development also targeting adult and pediatric malignancies. Day One Biopharmaceuticals was incorporated in Delaware in 2018 and maintains headquarters in Brisbane, California. The company operates primarily in the United States market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.04 | $-1.04 | -2.0% | |
| 2024 | $-1.02 | $-1.02 | +57.0% | |
| 2023 | $-2.37 | $-2.37 | -9.2% | |
| 2022 | $-2.17 | $-2.17 | — | |
| 2021 | — | — | — |